Physician profile
Rajkumar Doshi
NPI 1962906578
$1,962.01
in general payments reported to CMS, 2019-2025
12 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,000 · 2022: $173 · 2023: $163 · 2024: $136 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,000.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $269.41 | 2022-2024 | Camzyos, Eliquis |
| Amgen INC. | $126.52 | 2024-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $126.25 | 2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $109.81 | 2024-2025 | |
| Pfizer INC. | $107.73 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $99.99 | 2022 | |
| Abiomed | $31.47 | 2024 | Impella |
| Boston Scientific Corporation | $28.46 | 2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.24 | 2024 | Lifevest |
| Abbott Laboratories | $21.83 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $15.30 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajkumar Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.